CACNA1B and prostate carcinoma: CACNA1B (Cav2.2) is the only member in N-type VGCC family, and CACNA1B (Cav2.2) overexpression has been detected in breast and prostate cancer [15], and it represents a novel therapeutic target for the treatment of breast and prostate cancer.